AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30680661 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 12
Study 30680676 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0
Study 30680676 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study 30680712 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647263 administered every week (QW)
Number of subjects: 48
Study 30680712 — intervention group
Group type: COMPARATOR
Intervention: PF-06647263 administered every 3 weeks (Q3W)
Number of subjects: 48
Study 30680712 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06647263 at the recommended phase 2 dose (RP2D) of 0.015 mg/kg QW
Number of subjects: 48
Study 30681243 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry
Number of subjects: 21
Study 30681243 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched subjects without IPF)
Number of subjects: 21
Study 30681243 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time exhaled breath analysis
Number of subjects: 21
Study 30681262 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe calcification
Number of subjects: 350
Study 30681262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate calcification
Number of subjects: 350
Study 30681262 — intervention group
Group type: EXPERIMENTAL
Intervention: None/mild calcification
Number of subjects: 350
Study 30681551 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb treatment (2 consecutive 24-hour treatments)
Number of subjects: 30
Study 30681551 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 matched controls with advanced hemodynamic monitoring)
Number of subjects: 30
Study 30681643 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 rs2230199 GG genotype in ARI2 group (55.9%)
Number of subjects: 68
Study 30681643 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS2 (rs10490924) T allele and CFH (rs1061170) C allele
Number of subjects: 68
Study 30681793 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 (deoxycholic acid injection)
Number of subjects: 1029
Study 30681793 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-based devices
Number of subjects: 1029
Study 30681793 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical liposuction
Number of subjects: 1029
Study 30681793 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser liposuction
Number of subjects: 1029
Study 30681793 — intervention group
Group type: EXPERIMENTAL
Intervention: Other treatments
Number of subjects: 1029
Study 30681793 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1029
Study 30681798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity precision RF and fractional laser therapy
Number of subjects: 19
Study 30681965 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-BP app for hypertension self-management
Number of subjects: 396
Study 30681965 — intervention group
Group type: COMPARATOR
Intervention: Usual care methods
Number of subjects: 396
Study 30681964 — intervention group
Group type: EXPERIMENTAL
Intervention: LYNX mobile app
Number of subjects: 60
Study 30681964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 30682081 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile likelihood based pointwise confidence intervals (CIs) for a nonlinear dose-response model.
Number of subjects: 0
Study 30682081 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile likelihood based pointwise confidence intervals (CIs) for nonlinear dose-response models.
Number of subjects: 0
Study 30682530 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD symptom severity
Number of subjects: 80
Study 30682562 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody valve implant
Number of subjects: 136
Study 30683193 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular TAAA repair using a stent graft
Number of subjects: 142
Study 30683424 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS 2G implantation
Number of subjects: 24
Study 30683464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian networks
Number of subjects: 0
Study 30683464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous time Bayesian networks
Number of subjects: 0
Study 30683464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian networks (ignoring time)
Number of subjects: 0
Study 30683996 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 34
Study 30683996 — intervention group
Group type: COMPARATOR
Intervention: Previous immunisation with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 34
Study 30684076 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily for 24 weeks
Number of subjects: 9
Study 30684309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide oral suspension
Number of subjects: 10
Study 30684428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone use
Number of subjects: 2
Study 30684432 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook smoking cessation intervention with monetary incentive (up to US $90 for posting)
Number of subjects: 138
Study 30684432 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook smoking cessation intervention without monetary incentive
Number of subjects: 138
Study 30684432 — intervention group
Group type: COMPARATOR
Intervention: Not Ready group (incentive)
Number of subjects: 138
Study 30684432 — intervention group
Group type: COMPARATOR
Intervention: Not Ready group (no incentive)
Number of subjects: 138
Study 30684432 — intervention group
Group type: COMPARATOR
Intervention: Thinking and Getting Ready groups
Number of subjects: 138
Study 30684438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management app (StressProffen) developed based on cognitive behavioral strategies, usability tested with cancer survivors (n=6), healthy volunteers (n=7), healthcare providers (n=2), and eHealth experts (n=5).
Number of subjects: 48
Study 30684505 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intensified insulin therapy (EBIIT)
Number of subjects: 151
Study 30685284 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 60
Study 30685284 — intervention group
Group type: COMPARATOR
Intervention: No negative LARC stories
Number of subjects: 60
Study 30685284 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative LARC stories
Number of subjects: 60
Study 30685334 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent exacerbators
Number of subjects: 52
Study 30685334 — intervention group
Group type: COMPARATOR
Intervention: Nonfrequent exacerbators
Number of subjects: 52
Study 30685564 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 67
Study 30685564 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 67
Study 30685579 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 409
Study 30685579 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS score
Number of subjects: 409
Study 30685808 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF-primed haplo-identical HSCT (Haplo-ID)
Number of subjects: 131
Study 30685808 — intervention group
Group type: COMPARATOR
Intervention: HLA-identical HSCT (HLA-ID)
Number of subjects: 131
Study 30686306 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased portal flow pulsatility fraction (≥50%)
Number of subjects: 115
Study 30686306 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic right ventricular dysfunction
Number of subjects: 115
Study 30686306 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic right ventricular dysfunction
Number of subjects: 115
Study 30686306 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal flow assessment
Number of subjects: 115
Study 30686303 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NLR >4
Number of subjects: 1652
Study 30686303 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte count (lower)
Number of subjects: 1652
Study 30686303 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative monocyte count (higher)
Number of subjects: 1652
Study 30686303 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte ROS generation
Number of subjects: 1652
Study 30686308 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative care in paediatric surgical patients
Number of subjects: 2024
Study 30686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate/unwanted comments or behavior by male veterans
Number of subjects: 1395
Study 30686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of harassment
Number of subjects: 1395
Study 30686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling welcome at VA
Number of subjects: 1395
Study 30686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling safe at VA
Number of subjects: 1395
Study 30686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying/missing care
Number of subjects: 1395
Study 30686583 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral cortisol (CORT)
Number of subjects: 65
Study 30686583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30686586 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb114 5 mg/kg
Number of subjects: 19
Study 30686586 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb114 25 mg/kg
Number of subjects: 19
Study 30686586 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb114 50 mg/kg
Number of subjects: 19
Study 30686586 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb114 (all doses)
Number of subjects: 19
Study 30686586 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb114
Number of subjects: 19
Study 30686676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of PLX-PAD cells
Number of subjects: 246
Study 30686676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 30686756 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin added to abiraterone at 1000 mg twice daily in uninterrupted 4-week cycles
Number of subjects: 25
Study 30686767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor 100 mg and ivacaftor 125 mg (bodyweight <14 kg) or lumacaftor 150 mg and ivacaftor 188 mg (bodyweight ≥14 kg) orally every 12 h for 15 days (part A) and for 24 weeks (part B)
Number of subjects: 72
Study 30686953 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular stimulus
Number of subjects: 32
Study 30686953 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular stimulus
Number of subjects: 32
Study 30686953 — intervention group
Group type: COMPARATOR
Intervention: Pinhole glasses
Number of subjects: 32
Study 30686953 — intervention group
Group type: COMPARATOR
Intervention: Monocular stimulus (dominant eye, non-dominant eye, ipsilateral, contralateral)
Number of subjects: 32
Study 30686953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger refractive stimuli
Number of subjects: 32
Study 30687117 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol Rich Curry
Number of subjects: 0
Study 30687117 — intervention group
Group type: COMPARATOR
Intervention: Control (no curry or lower doses)
Number of subjects: 0
Study 30687164 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Education Program (PEP), 2 hours per week for 16 weeks
Number of subjects: 119
Study 30687164 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 119
Study 30687208 — intervention group
Group type: EXPERIMENTAL
Intervention: Games for Older Adults Active Life (GOAL) Project intervention, details not available
Number of subjects: 0
Study 30687208 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 30687504 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic partial pleurectomy/decortication (VAT-PD)
Number of subjects: 38
Study 30687504 — intervention group
Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 38
Study 30687504 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 38
Study 30687508 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary artery function-guided diagnosis and treatment
Number of subjects: 150
Study 30687508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric CMR assessment
Number of subjects: 150
Study 30687508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric CMR
Number of subjects: 150
Study 30687508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no invasive coronary artery function-guided diagnosis and treatment)
Number of subjects: 150
Study 30687584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation orderly (AO)
Number of subjects: 36
Study 30687584 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 30687714 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin Phytosome (CP) 2 g/day for 2 weeks
Number of subjects: 7
Study 30687792 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine, details on dosage and duration not available
Number of subjects: 0
Study 30687792 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 30687799 — intervention group
Group type: EXPERIMENTAL
Intervention: SURgical PAtient Safety System (SURPASS) checklists combined with WHO Surgical Safety Checklist (WHO SSC)
Number of subjects: 29
Study 30687799 — intervention group
Group type: EXPERIMENTAL
Intervention: SURPASS checklists
Number of subjects: 29
Study 30687970 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 10% (1 g/kg daily)
Number of subjects: 40
Study 30688008 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (protease-inhibitor-free)
Number of subjects: 61
Study 30688175 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert interventions delivered via telehealth
Number of subjects: 33
Study 30688175 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and skills related to behavioral and psychological symptoms of dementia, disease expectations, safety, activities of daily living, medical care optimization, and medication utilization
Number of subjects: 33
Study 30688175 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver support interventions including respite, positive reinforcement, social and financial support, and self-care
Number of subjects: 33
Study 30688272 — intervention group
Group type: EXPERIMENTAL
Intervention: Moyamoya disease
Number of subjects: 34
Study 30688272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular atherosclerotic disease
Number of subjects: 34
Study 30688272 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 34
Study 30688654 — intervention group
Group type: EXPERIMENTAL
Intervention: breathe intervention (mHealth platform)
Number of subjects: 138
Study 30688888 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft adipose matrix
Number of subjects: 0
Study 30688903 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 40
Study 30688903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 30689042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day for 26 weeks (rasagiline-rasagiline group)
Number of subjects: 198
Study 30689042 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline 1 mg/day for 26 weeks (placebo-rasagiline group)
Number of subjects: 198
Study 30689105 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency localization system (RFLS)
Number of subjects: 50
Study 30689688 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants without rule violations (n = 162)
Number of subjects: 320
Study 30689688 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with rule violations (n = 158)
Number of subjects: 320
Study 30689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg weekly) combined with cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3 weeks for a maximum of six cycles
Number of subjects: 35
Study 30689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (≥2400 mg) and ≥4 cycles of PF
Number of subjects: 35
Study 30689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab-PF chemotherapy
Number of subjects: 35
Study 30689759 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose)
Number of subjects: 416
Study 30689759 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 416
Study 30689814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontuberculous mycobacteria isolation
Number of subjects: 427
Study 30689814 — intervention group
Group type: EXPERIMENTAL
Intervention: Southeast Asian origin, age 5-9 years, and severe immunodeficiency
Number of subjects: 427
Study 30689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 132
Study 30689904 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 132
Study 30689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 132
Study 30689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-glutamyl transferase
Number of subjects: 132
Study 30689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum adiponectin
Number of subjects: 132
Study 30689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered liver and adipose tissue function
Number of subjects: 132
Study 30689971 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan Controlled Attenuation Parameter (CAP)
Number of subjects: 450
Study 30689971 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Stiffness Measurement (LSM)
Number of subjects: 450
Study 30689972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4908
Study 30689972 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 4908
Study 30689972 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4908
Study 30690141 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon (DCB)
Number of subjects: 1980
Study 30690141 — intervention group
Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty (PTA)
Number of subjects: 1980
Study 30690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) with positive nodal stage
Number of subjects: 0
Study 30690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing tumor size and higher nodal stage
Number of subjects: 0
Study 30690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal stage
Number of subjects: 0
Study 30690254 — intervention group
Group type: COMPARATOR
Intervention: Nodal-negative tumors (pN0)
Number of subjects: 0
Study 30690646 — intervention group
Group type: EXPERIMENTAL
Intervention: MEESSI-AHF score calculation
Number of subjects: 1572
Study 30691261 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry data collection and analysis
Number of subjects: 134
Study 30691339 — intervention group
Group type: COMPARATOR
Intervention: Prior warfarin treatment with INR <2
Number of subjects: 1189
Study 30691339 — intervention group
Group type: COMPARATOR
Intervention: Prior warfarin treatment with INR ≥2
Number of subjects: 1189
Study 30691339 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior anticoagulation
Number of subjects: 1189
Study 30691429 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP
Number of subjects: 59
Study 30691429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 59
Study 30691480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored support for implementing social determinants of health documentation
Number of subjects: 30
Study 30691536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadenotucirev monotherapy
Number of subjects: 61
Study 30691827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal lavage with intraductal infusion of corticosteroids and antimicrobial agents, followed by breast massage for 2 weeks.
Number of subjects: 32
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation for pulmonary embolism (PE)
Number of subjects: 9091
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer test
Number of subjects: 9091
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-perfusion scan
Number of subjects: 9091
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: CT pulmonary angiography
Number of subjects: 9091
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall serious outcomes
Number of subjects: 9091
Study 30691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpulmonary embolism serious condition
Number of subjects: 9091
Study 30692121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle
Number of subjects: 27
Study 30692613 — intervention group
Group type: EXPERIMENTAL
Intervention: Late cranial ultrasound (CUS) abnormalities
Number of subjects: 433
Study 30692613 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter abnormality (WMA) on near-term brain MRI (ntMRI)
Number of subjects: 433
Study 30692613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III scores
Number of subjects: 433
Study 30692613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 433
Study 30692613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand function deficits
Number of subjects: 433
Study 30693086 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time compression feedback using the Cardio First Angel™ (CFA) device
Number of subjects: 900
Study 30693086 — intervention group
Group type: COMPARATOR
Intervention: Standard manual chest compressions
Number of subjects: 900
Study 30693097 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group treatment
Number of subjects: 0
Study 30693097 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0